Morgan Stanley Maintains BioNTech(BNTX.US) With Hold Rating, Maintains Target Price $101

Morgan Stanley analyst Terence Flynn maintains $BioNTech(BNTX.US)$ with a hold rating, and maintains the target price at $101.According to TipRanks data, the analyst has a success rate of 65.1% and a

Futu NewsJul 1 21:31 · Ratings

Morgan Stanley Sticks to Its Hold Rating for BioNTech SE (BNTX)

TipRanksJul 1 20:35

Andreas & Thomas Struengmann Award Honors HAYA Therapeutics Co-founders as Inaugural Winners

The award jury selected Samir Ounzain, PhD and Daniel Blessing, PhD, the two co-founders of HAYA Therapeutics, as the winners from an outstanding finalist group of life science entrepreneurs Represe

BusinesswireJul 1 13:00

European Equities Traded in the US as American Depositary Receipts Nudge Higher in Friday Trading

European equities traded in the US as American depositary receipts were moving slightly higher late Friday morning, rising 0.12% to 1,424.97 on the S&P Europe Select ADR Index. However, the gain likel

MT NewswiresJun 28 23:06

Pfizer (PFE), BioNTech's Updated COVID-19 Jab Gets CHMP Nod

Yahoo FinanceJun 28 23:02

One graphic to understand | the June bull and bear stocklist of U.S. stocks is released! Optional consumer and technology sectors are performing strongly, Arm rose more than 38%, and Adobe rose nearly 23%.

The three major US stock indexes rose collectively this month, putting a perfect end to the first half of the year. Large-cap tech stocks continued their rally, driving the Nasdaq up by 6.71% this month, the best performer. The S&P 500 rose 3.89% this month and the Dow Jones rose 1.23%.

Futu NewsJun 28 19:50